Skip to content

Serotonin: all studies

Page 322 of 400: studies 3,211 to 3,220 of 3,999, newest first. Back to the serotonin overview

Research

Psychedelics As A New Anti‐Inflammatory Therapeutic For Atherosclerosis

The FASEB Journal April 1, 2017 C. Nichols, Melaine N. Sebastian, Thomas W. Flanagan

We previously discovered that serotonin 5‐HT2A receptor activation with psychedelics has potent anti‐inflammatory activity in both cell culture and whole animals, which indicated potent anti‐inflammatory effects in vascular tissues among others. More recently we found that the psychedelic (R)‐DOI potently prevents the development of allergic asthma in a mouse model. The effects of (R)‐DOI were...

Cannabinoids Activate Monoaminergic Signaling to Modulate Key C. elegans Behaviors.

Journal of Neuroscience March 15, 2017 Mitchell D Oakes, Wen Jing Law, Tobias Clark et al.

Cannabis sativa, or marijuana, a popular recreational drug, alters sensory perception and exerts a range of potential medicinal benefits. The present study demonstrates that the endogenous cannabinoid receptor agonists 2-arachidonoylglycerol (2-AG) and anandamide (AEA) activate a canonical cannabinoid receptor in Caenorhabditis elegans and also modulate monoaminergic signaling at multiple...

DOI: 10.1523/jneurosci.3151-16.2017 (opens in new tab) Full text (opens in new tab) C. elegans Cannabinoid Monoamine Neuromodulation +1

Genetic Correlates of Spirituality/Religion and Depression: A Study in Offspring and Grandchildren at High and Low Familial Risk for Depression.

Spirituality in Clinical Practice March 1, 2017 Micheline R Anderson, Lisa Miller, Priya Wickramaratne et al.

Rationale: Possible genetic correlates of spirituality and depression have been identified in community samples. We investigate some of the previously identified candidates in a sample of families at both high and low-risk for depression. Method: Offspring and grandchildren of individuals at high and low-risk for depression, participating in a multi-wave thirty-year longitudinal study, were...

Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms.

Noro psikiyatri arsivi March 2017 Berker Duman, Nilay Sedes, Bora Baskak

Methylenedioxymethamphetamine (MDMA) is an amphetamine-derived psychostimulant, usually known as "ecstasy." The long-term neuropsychological effects of MDMA are examined in several studies with conflicting results. The most common findings reported are depression, anxiety, and memory and attention deficits. In addition to acute psychotic reactions observed after MDMA use, serotonergic and...

DOI: 10.5152/npa.2017.16964 (opens in new tab) Full text (opens in new tab) Psychotic disorders Substance-induced psychosis Substance-related disorders

The fibrinolytic system: A new target for treatment of depression with psychedelics.

Medical Hypotheses March 2017 R D Idell, G Florova, A A Komissarov et al.

Current understanding of the neurobiology of depression has grown over the past few years beyond the traditional monoamine theory of depression to include chronic stress, inflammation and disrupted synaptic plasticity. Tissue plasminogen activator (tPA) is a key factor that not only promotes fibrinolysis via the activation of plasminogen, but also contributes to regulation of synaptic...

Disrupted integration of sensory stimuli with information about the movement of the body as a mechanism explaining LSD-induced experience.

Medical Hypotheses March 1, 2017 Grzegorz R Juszczak 4 citations

LSD (lysergic acid diethylamide) is a model psychedelic drug used to study mechanism underlying the effects induced by hallucinogens. However, despite advanced knowledge about molecular mechanism responsible for the effects induced by LSD and other related substances acting at serotonergic 5-HT2a receptors, we still do not understand how these drugs trigger specific sensory experiences....

Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies

Therapeutic Advances in Psychopharmacology February 23, 2017 Rafael G. Dos Santos, José Carlos Bouso, Jaime E. C. Hallak 167 citations

Ayahuasca is a hallucinogen brew traditionally used for ritual and therapeutic purposes in Northwestern Amazon. It is rich in the tryptamine hallucinogens dimethyltryptamine (DMT), which acts as a serotonin 5-HT 2A agonist. This mechanism of action is similar to other compounds such as lysergic acid diethylamide (LSD) and psilocybin. The controlled use of LSD and psilocybin in experimental...

Psychiatric aspects of designer drugs and new psychoactive substances consumption

Interactive science February 22, 2017 Vladimir Valerievich Mrykhin, Andrey Viktorovich Antsyborov 2 citations

According to the authors, appeared not long ago new psychoactive substances (designer drugs), including synthetic cannabinoids, derivatives of cathinone, phenethylamines, new stimulants, synthetic opioids, tryptamine derivatives, phencyclidine, piperazine, agonists of GABA (A/B) receptors have become a serious problem for both consumers and doctors. Consumers of these substances are attracted...

DOI: 10.21661/r-116849 (opens in new tab) Full text (opens in new tab) Designer drug Psychoactive substance Consumption sociology Mephedrone +1

Altered Insula Connectivity under MDMA.

Neuropsychopharmacology February 14, 2017 Ishan C Walpola, Timothy Nest, Leor Roseman et al. 50 citations

Recent work with noninvasive human brain imaging has started to investigate the effects of 3,4-methylenedioxymethamphetamine (MDMA) on large-scale patterns of brain activity. MDMA, a potent monoamine-releaser with particularly pronounced serotonin- releasing properties, has unique subjective effects that include: marked positive mood, pleasant/unusual bodily sensations and pro-social, empathic...

DOI: 10.1038/npp.2017.35 (opens in new tab) Full text (opens in new tab) MDMA Research MDMA Studies Ecstasy research Psychedelic research +24